Figure 2From: The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen Schedule of assessment visits, medication titration and monitoring of adverse events and falls. Back to article page